LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 32

Search options

  1. Article ; Online: First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology.

    Kang, Jung Julie / Reiter, Robert E / Steinberg, Michael L / King, Christopher R

    European urology oncology

    2018  Volume 1, Issue 5, Page(s) 378–385

    Abstract: Background: Ultrasensitive prostate-specific antigen (uPSA) has untapped potential for optimizing management following radical prostatectomy (RP) in terms of facilitating early salvage, minimizing overtreatment, and identifying those at risk of occult ... ...

    Abstract Background: Ultrasensitive prostate-specific antigen (uPSA) has untapped potential for optimizing management following radical prostatectomy (RP) in terms of facilitating early salvage, minimizing overtreatment, and identifying those at risk of occult systemic disease.
    Objective: To test first postoperative uPSA for prediction of outcome in patients with adverse pathology after RP.
    Design, setting, and participants: Patients with extraprostatic extension and/or a positive margin who did not receive immediate adjuvant therapy.
    Outcome measurements and statistical analysis: First uPSA was measured at 3 mo after RP. The study endpoints were biochemical relapse (BCR), defined as PSA ≥0.2ng/ml, bone metastasis-free survival (BMFS), prostate cancer-specific survival (PCSS), overall survival (OS), and salvage radiation therapy (SRT) success. Outcome results were compared using the Kaplan-Meier method and multivariate analysis (MVA).
    Results and limitations: The cohort consisted of 269 RP patients from 1991-2015 with median follow-up of 77 mo. Sensitivity analysis identified first postoperative uPSA of ≥0.03ng/ml as the optimal threshold for predicting BCR. First postoperative uPSA ≥0.03 versus <0.03ng/ml was associated with worse 5-yr BCR (86%, 95% confidence interval [CI] 71-93% vs 39%, 95% CI 25-51%; p<0.00001), 10-yr BMFS (75%, 95% CI 62-92% vs 95%, 95% CI 88-100%; p=0.0001), 10-yr PCSS (84%, 95% CI 73-96% vs 100%, 95% CI 100-100%; p=0.005), and 10-yr OS (81%, 95% CI 70-93% vs 98%, 95% CI 94-100%; p=0.009). On MVA, first postoperative uPSA ≥0.03ng/ml was an independent predictor of BCR (hazard ratio [HR] 9.4, 95% CI 5.8-15.4; p<0.00001) and the only predictor for BMFS (HR 9.7, 95% CI 2.1-44.6; p=0.0034), PCSS (HR 13.5, 95% CI 1.7-107.9; p=0.014), and OS (HR 5.0, 95% CI 1.4-18.3; p=0.014). Following SRT, first postoperative uPSA ≥0.03ng/ml independently predicted worse BMFS (HR 5.9, 95% CI 1.3-26.9; p=0.021), PCSS (HR 6.9, 95% CI 0.9-55.8; p=0.07), and OS (4.5, 95% CI 1.0-20.1; p=0.057). Limitations include the retrospective design and potential selection bias.
    Conclusions: First postoperative uPSA ≥0.03ng/ml independently predicts BCR, BMFS, PCSS, and OS better than traditional risk factors. SRT alone may be insufficient for patients with high-risk disease when first postoperative uPSA is ≥0.03ng/ml.
    Patient summary: When the first postprostatectomy ultrasensitive prostate-specific antigen level is ≥0.03ng/ml, patients are at higher risk of recurrent and occult prostate cancer. They should be considered for early salvage radiotherapy, possibly with hormone therapy.
    MeSH term(s) Aged ; Follow-Up Studies ; Humans ; Male ; Margins of Excision ; Middle Aged ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/radiotherapy ; Neoplasm Staging ; Neoplasm, Residual ; Postoperative Period ; Prognosis ; Prostate-Specific Antigen/analysis ; Prostate-Specific Antigen/blood ; Prostatectomy ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/surgery ; Radiotherapy, Adjuvant/statistics & numerical data ; Retrospective Studies ; Risk Factors ; Salvage Therapy/statistics & numerical data ; Survival Analysis
    Chemical Substances Prostate-Specific Antigen (EC 3.4.21.77)
    Language English
    Publishing date 2018-08-22
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2588-9311
    ISSN (online) 2588-9311
    DOI 10.1016/j.euo.2018.07.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: In reply to Sharma et al.

    Lee, Percy / Kang, Jung Julie

    International journal of radiation oncology, biology, physics

    2013  Volume 87, Issue 4, Page(s) 631–632

    MeSH term(s) Brain Neoplasms/radiotherapy ; Female ; Glioblastoma/radiotherapy ; Humans ; Male ; Neoplastic Stem Cells/radiation effects
    Language English
    Publishing date 2013-11-15
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 197614-x
    ISSN 1879-355X ; 0360-3016
    ISSN (online) 1879-355X
    ISSN 0360-3016
    DOI 10.1016/j.ijrobp.2013.07.027
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer.

    Han, James / Zakeri, Kaveh / Raab, Gabriel / Hesse, Jennifer / Shamseddine, Achraf / Chen, Linda / Yu, Yao / Kang, Jung Julie / McBride, Sean M / Riaz, Nadeem / Tsai, C Jillian / Gelblum, Daphna / Sherman, Eric J / Wong, Richard J / Michel, Loren / Lee, Nancy Y

    Head & neck

    2023  Volume 45, Issue 9, Page(s) 2207–2216

    Abstract: Background: We report the outcomes of cisplatin-ineligible HNSCC patients treated with definitive chemoradiation and concurrent carboplatin and paclitaxel.: Materials and methods: We included consecutive HNSCC patients treated from 2013 to 2021 that ... ...

    Abstract Background: We report the outcomes of cisplatin-ineligible HNSCC patients treated with definitive chemoradiation and concurrent carboplatin and paclitaxel.
    Materials and methods: We included consecutive HNSCC patients treated from 2013 to 2021 that received definitive chemoradiation with carboplatin and paclitaxel. Locoregional recurrences (LRR) and distant metastases (DM) were estimated using cumulative incidence functions. Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier methods.
    Results: Sixty-five patients were identified with median age of 71 years (range 44-85). Median radiation dose was 70 Gy and the median doses of carboplatin and paclitaxel were AUC 1 and 40 mg/m
    Conclusions: Chemoradiation with carboplatin and paclitaxel is an excellent option for cisplatin-ineligible HNSCC patients.
    MeSH term(s) Humans ; Adult ; Middle Aged ; Aged ; Aged, 80 and over ; Carboplatin/therapeutic use ; Paclitaxel ; Cisplatin/therapeutic use ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neoplasm Recurrence, Local/drug therapy ; Head and Neck Neoplasms/drug therapy ; Chemoradiotherapy/adverse effects
    Chemical Substances Carboplatin (BG3F62OND5) ; Paclitaxel (P88XT4IS4D) ; Cisplatin (Q20Q21Q62J)
    Language English
    Publishing date 2023-07-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 645165-2
    ISSN 1097-0347 ; 0148-6403 ; 1043-3074
    ISSN (online) 1097-0347
    ISSN 0148-6403 ; 1043-3074
    DOI 10.1002/hed.27456
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Peer Review of Head and Neck Cancer Planning Target Volumes in Radiation Oncology.

    Hesse, Jennifer / Chen, Linda / Yu, Yao / Kang, Jung Julie / Riaz, Nadeem / Tsai, C Jillian / McBride, Sean M / Gelblum, Daphna / Zakeri, Kaveh / Lee, Nancy Y

    Advances in radiation oncology

    2022  Volume 7, Issue 3, Page(s) 100917

    Abstract: Purpose: Radiation treatment plans undergo peer review during chart rounds, but changes to treatment volumes would require replanning. Our group implemented weekly head and neck cancer "volume rounds" to peer review all target volumes for head and neck ... ...

    Abstract Purpose: Radiation treatment plans undergo peer review during chart rounds, but changes to treatment volumes would require replanning. Our group implemented weekly head and neck cancer "volume rounds" to peer review all target volumes for head and neck cancer before radiation therapy (RT) planning and chart rounds.
    Methods and materials: We analyzed modifications made to planning target volumes (PTVs) at volume rounds for consecutive nonproton head and neck cancer cases from May 2020 to May 2021. Nine head and neck radiation oncologists participated in weekly volume rounds during this time. Recommendations were categorized as no changes, minor changes, major changes, additional workup (eg, biopsy or imaging), and consultation or tumor board discussion needed before the start of RT. Minor changes to PTVs generally did not require a second review before treatment planning while major changes did.
    Results: PTVs for 511 cases involving 432 patients underwent peer review and 298 (58.3%) of these cases did not require any modifications before treatment planning. Minor and major changes were recommended in 75 (14.7%) and 86 (16.8%) cases, respectively. Forty-five (8.8%) cases were recommended to have additional workup and 23 (4.5%) required additional consultation with nonradiation surgeons or medical oncologists. Of the 45 cases that were recommended for additional workup, 40 underwent biopsy or imaging. Positive findings on imaging or biopsy occurred in 13 patients, leading to a significant change in management, including 4 patients who underwent additional surgery after positive findings before the start of RT.
    Conclusions: Prospective peer review during head and neck cancer volume rounds led to frequent minor and major alterations to PTVs. Significant changes in the overall treatment plan, such as additional surgery before start of RT, occurred in a minority of patients.
    Language English
    Publishing date 2022-02-06
    Publishing country United States
    Document type Journal Article
    ISSN 2452-1094
    ISSN 2452-1094
    DOI 10.1016/j.adro.2022.100917
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Outcomes for Organ Preservation with Chemoradiation Therapy for T4 Larynx and Hypopharynx Cancer.

    Eita, Amgad / Mohamed, Nader / Rybkin, Alisa / Kang, Jung Julie / Fiasconaro, Megan / Zhigang, Zhang / Zakeri, Kaveh / Yu, Yao / Sadaka, Emad / Sherman, Eric / Dunn, Lara / Cracchiolo, Jennifer / Wong, Richard J / Cohen, Marc / Lee, Nancy Y

    The Laryngoscope

    2022  Volume 133, Issue 5, Page(s) 1138–1145

    Abstract: Objective: Limited data is available to guide non-surgical management of Stage T4 larynx and hypopharynx cancer patients who have inoperable disease or refuse surgery. We aim to review the nonoperative management of T4 laryngeal and hypopharyngeal ... ...

    Abstract Objective: Limited data is available to guide non-surgical management of Stage T4 larynx and hypopharynx cancer patients who have inoperable disease or refuse surgery. We aim to review the nonoperative management of T4 laryngeal and hypopharyngeal cancer and report the long-term therapeutic and functional outcomes.
    Methods: We reviewed the nonoperative management of T4 laryngeal (n = 44) and hypopharyngeal (n = 53) cancer from 1997 to 2015 and performed a univariate analysis (UVA).
    Results: The 2-/5-year OS rates were 73%/38% for larynx patients and 52%/29% for hypopharynx patients. Locoregional failure (LRF) occurred in 25% and 19% of larynx and hypopharynx patients, respectively. On UVA of the larynx subset, N3 nodal status and non-intensity-modulated radiation therapy were negatively associated with OS; treatment with radiation therapy alone impacted disease-free survival; and age >70 was associated with LRF. On UVA of the hypopharynx subset, only T4b status significantly impacted OS. In the larynx and hypopharynx groups, 68% and 85% received a percutaneous endoscopic gastrostomy (PEG) tube and 32% and 40% received a tracheostomy tube, respectively. At the last follow-up visit, 66% of our larynx cohort had neither tracheostomy or PEG placed and 40% of our hypopharynx cohort had neither.
    Conclusion: We report better than previously noted outcomes among T4 larynx and hypopharynx patients who have unresectable disease or refuse surgery.
    Level of evidence: 4 Laryngoscope, 133:1138-1145, 2023.
    MeSH term(s) Humans ; Hypopharyngeal Neoplasms/pathology ; Hypopharynx/pathology ; Laryngeal Neoplasms/pathology ; Organ Preservation ; Neoplasm Staging ; Carcinoma, Squamous Cell/pathology ; Larynx/surgery
    Language English
    Publishing date 2022-07-08
    Publishing country United States
    Document type Review ; Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 80180-x
    ISSN 1531-4995 ; 0023-852X
    ISSN (online) 1531-4995
    ISSN 0023-852X
    DOI 10.1002/lary.30279
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy.

    Youssef, Irini / Yoon, Jennifer / Mohamed, Nader / Zakeri, Kaveh / Press, Robert H / Yu, Yao / Kang, Jung Julie / Wong, Richard J / Tuttle, R Michael / Shaha, Ashok / Sherman, Eric / Lee, Nancy Y

    International journal of particle therapy

    2022  Volume 9, Issue 2, Page(s) 20–30

    Abstract: Purpose: Proton therapy is an emerging therapy for several malignancies owing to its favorable therapeutic ratio. There are very limited data on the use of proton therapy in the management of thyroid carcinoma. Our objective was to review the safety, ... ...

    Abstract Purpose: Proton therapy is an emerging therapy for several malignancies owing to its favorable therapeutic ratio. There are very limited data on the use of proton therapy in the management of thyroid carcinoma. Our objective was to review the safety, feasibility, and outcomes of proton therapy for patients with thyroid cancer treated to the head and neck.
    Methods: From our institution's proton database from 2012 to 2021, we identified 22 patients with thyroid cancer treated with proton beam therapy. We evaluated outcomes and toxicities.
    Results: Median follow-up was 26 months. Of the 22 patients, 50% were female. The mean age was 65 years. Three patients had anaplastic cancer; 13, papillary carcinoma; 2, follicular carcinoma; and 2, poorly differentiated carcinoma. Forty-six percent had T4 disease. Primary targets were the central neck compartment, level VI, and upper mediastinum. Radiation dose was 60 GyRBE adjuvantly, and 70 GyRBE for gross disease (range, 6000-7600 GyRBE). Eight patients underwent upfront adjuvant radiation, and 3 received definitive radiation for unresectable disease upfront. Eleven patients received either salvage or palliative radiation. Fifty-nine percent of patients had extrathyroidal extension, and 64% of patients had gross disease in the neck before treatment. Fifty percent of patients had metastatic disease before treatment. Sixteen patients received concurrent chemotherapy, 63% of these patients received doxorubicin. For all patients, 1-year local regional recurrence (LRR) was 0%, and overall survival (OS) was 90%. Acute grade 3+ toxicities occurred in 27% of patients, the most frequent being dermatitis (27%). Three patients required a percutaneous endoscopic gastrostomy tube after radiation therapy (RT), 2 owing to progression. There were no grade 4+ toxicities.
    Conclusions: Proton therapy for thyroid cancer appears feasible and effective with minimal toxicities. Prospective studies comparing proton therapy with intensity-modulated RT, to evaluate the clinical efficacy of using proton therapy to reduce toxicities in patients undergoing radiation for thyroid cancer, are warranted.
    Language English
    Publishing date 2022-07-15
    Publishing country United States
    Document type Journal Article
    ISSN 2331-5180
    ISSN (online) 2331-5180
    DOI 10.14338/IJPT-22-00005.1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy.

    Kang, Jung Julie / Reiter, Robert E / Steinberg, Michael L / King, Christopher R

    The Journal of urology

    2015  Volume 193, Issue 5, Page(s) 1532–1538

    Abstract: Purpose: Integrating ultrasensitive prostate specific antigen with surveillance in patients at high risk after radical prostatectomy potentially optimizes treatment by correctly identifying recurrence, promoting an early salvage strategy and minimizing ... ...

    Abstract Purpose: Integrating ultrasensitive prostate specific antigen with surveillance in patients at high risk after radical prostatectomy potentially optimizes treatment by correctly identifying recurrence, promoting an early salvage strategy and minimizing overtreatment. We tested the power of postoperative ultrasensitive prostate specific antigen to identify eventual biochemical failure.
    Materials and methods: We identified 247 patients at high risk with a median followup of 44 months who underwent radical prostatectomy from 1991 to 2013. Each patient had extraprostatic extension and/or a positive margin. Surgical technique, initial prostate specific antigen, pathology findings and postoperative prostate specific antigen were analyzed. The ultrasensitive prostate specific antigen assay threshold was 0.01 ng/ml. Conventional biochemical relapse was defined as prostate specific antigen 0.2 ng/ml or greater. Kaplan-Meier and Cox multivariate analyses were done to compare the rates of ultrasensitive prostate specific antigen recurrence and conventional biochemical relapse.
    Results: Sensitivity analysis revealed that ultrasensitive prostate specific antigen 0.03 ng/ml or greater was the optimal threshold to identify recurrence. A first postoperative ultrasensitive value of 0.03 ng/ml or greater, Gleason grade, T stage, initial prostate specific antigen and margin status predicted conventional biochemical relapse. On multivariate analysis only a first postoperative ultrasensitive value of 0.03 ng/ml or greater, Gleason grade and T stage independently predicted conventional biochemical relapse. First postoperative ultrasensitive prostate specific antigen 0.03 ng/ml or greater conferred the highest risk (HR 8.5, p < 0.0001) and identified conventional biochemical relapse with greater sensitivity than undetectable first conventional prostate specific antigen (70% vs 46%). Any postoperative prostate specific antigen 0.03 ng/ml or greater captured all failures missed by the first postoperative value (100% sensitivity) with accuracy (96% specificity). Defining failure at an ultrasensitive value of 0.03 ng/ml or greater yielded a median lead time advantage of 18 months (mean 24) over the conventional definition of prostate specific antigen 0.2 ng/ml or greater.
    Conclusions: Ultrasensitive prostate specific antigen 0.03 ng/ml or greater is an independent factor that identifies biochemical relapse more accurately than any traditional risk factors and confers a significant lead time advantage. This factor enables critical decisions on the timing of and indication for postoperative radiotherapy in patients at high risk after radical prostatectomy.
    MeSH term(s) Humans ; Male ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/radiotherapy ; Patient Selection ; Postoperative Care ; Prostate-Specific Antigen/blood ; Prostatectomy ; Prostatic Neoplasms/radiotherapy ; Prostatic Neoplasms/surgery ; Reproducibility of Results ; Retrospective Studies ; Sensitivity and Specificity
    Chemical Substances Prostate-Specific Antigen (EC 3.4.21.77)
    Language English
    Publishing date 2015-05
    Publishing country United States
    Document type Evaluation Studies ; Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 3176-8
    ISSN 1527-3792 ; 0022-5347
    ISSN (online) 1527-3792
    ISSN 0022-5347
    DOI 10.1016/j.juro.2014.11.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Impact of Telemedicine on Patient Satisfaction and Perceptions of Care Quality in Radiation Oncology.

    Shaverdian, Narek / Gillespie, Erin F / Cha, Elaine / Kim, Soo Young / Benvengo, Stephanie / Chino, Fumiko / Kang, Jung Julie / Li, Yuelin / Atkinson, Thomas M / Lee, Nancy / Washington, Charles M / Cahlon, Oren / Gomez, Daniel R

    Journal of the National Comprehensive Cancer Network : JNCCN

    2021  Volume 19, Issue 10, Page(s) 1174–1180

    Abstract: Background: The COVID-19 pandemic has transformed cancer care with the rapid expansion of telemedicine, but given the limited use of telemedicine in oncology, concerns have been raised about the quality of care being delivered. We assessed the patient ... ...

    Abstract Background: The COVID-19 pandemic has transformed cancer care with the rapid expansion of telemedicine, but given the limited use of telemedicine in oncology, concerns have been raised about the quality of care being delivered. We assessed the patient experience with telemedicine in routine radiation oncology practice to determine satisfaction, quality of care, and opportunities for optimization.
    Patients and methods: Patients seen within a multistate comprehensive cancer center for prepandemic office visits and intrapandemic telemedicine visits in December 2019 through June 2020 who completed patient experience questionnaires were evaluated. Patient satisfaction between office and telemedicine consultations were compared, patient visit-type preferences were assessed, and factors associated with an office visit preference were determined.
    Results: In total, 1,077 patients were assessed (office visit, n=726; telemedicine, n=351). The telemedicine-consult survey response rate was 40%. No significant differences were seen in satisfaction scores between office and telemedicine consultations, including the appointment experience versus expectation, quality of physician's explanation, and level of physician concern and friendliness. Among telemedicine survey respondents, 45% and 34% preferred telemedicine and office visits, respectively, and 21% had no preference for their visit type. Most respondents found their confidence in their physician (90%), understanding of the treatment plan (88%), and confidence in their treatment (87%) to be better or no different than with an office visit. Patients with better performance status and who were married/partnered were more likely to prefer in-person office visit consultations (odds ratio [OR], 1.04 [95% CI, 1.00-1.08]; P=.047, and 2.41 [95% CI, 1.14-5.47]; P=.009, respectively). Patients with telephone-only encounters were more likely to report better treatment plan understanding with an office visit (OR, 2.25; 95% CI, 1.00-4.77; P=.04).
    Conclusions: This study is the first to assess telemedicine in routine radiation oncology practice, and found high patient satisfaction and confidence in their care. Optimization of telemedicine in oncology should be a priority, specifically access to audiovisual capabilities that can improve patient-oncologist communication.
    MeSH term(s) COVID-19 ; Humans ; Pandemics ; Patient Satisfaction ; Perception ; Radiation Oncology ; SARS-CoV-2 ; Telemedicine
    Language English
    Publishing date 2021-01-04
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2250759-0
    ISSN 1540-1413 ; 1540-1405
    ISSN (online) 1540-1413
    ISSN 1540-1405
    DOI 10.6004/jnccn.2020.7687
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity.

    Yu, Yao / Schöder, Heiko / Zakeri, Kaveh / Chen, Linda / Kang, Jung Julie / McBride, Sean Matthew / Tsai, C Jillian / Gelblum, Daphna Y / Boyle, Jay O / Cracchiolo, Jennifer R / Cohen, Marc A / Singh, Bhuvanesh / Ganly, Ian / Patel, Snehal G / Michel, Loren S / Dunn, Lara / Sherman, Eric J / Pfister, David G / Wong, Richard J /
    Riaz, Nadeem / Lee, Nancy Y

    Oral oncology

    2023  Volume 141, Page(s) 106400

    Abstract: Background: We evaluate the impact of post-operative 18-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) for radiation planning on the detection of early recurrence (ER) and treatment outcomes in oral squamous cell ... ...

    Abstract Background: We evaluate the impact of post-operative 18-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) for radiation planning on the detection of early recurrence (ER) and treatment outcomes in oral squamous cell carcinoma (OSCC).
    Methods: We retrospectively reviewed the records of patients treated with post-operative radiation between 2005 and 2019 for OSCC at our institution. Extracapsular extension and positive surgical margins were classified as high risk features; pT3-4, node positivity, lymphovascular invasion, perineural invasion, tumor thickness >5 mm, and close surgical margins were considered intermediate risk features. Patients with ER were identified. Inverse probability of treatment weighting (IPTW) was used to adjust for imbalances between baseline characteristics.
    Results: 391 patients with OSCC were treated with post-operative radiation. 237 (60.6%) patients underwent post-operative PET/CT planning vs. 154 (39.4%) who were planned with CT only. Patients screened with post-operative PET/CT were more likely to be diagnosed with ER than those planned with CT only (16.5 vs. 3.3%, p < 0.0001). Among patients with ER, those with intermediate features were more likely than those high risk features to undergo major treatment intensification, including re-operation, the addition of chemotherapy, or intensification of radiation by ≥ 10 Gy (91% vs. 9%, p < 0.0001). Post-operative PET/CT was associated with improved disease-free and overall survival for patients with intermediate risk features (IPTW log-rank p = 0.026 and p = 0.047, respectively) but not high risk features (IPTW log-rank p = 0.44 and p = 0.96).
    Conclusions: Use of post-operative PET/CT is associated with increased detection of early recurrence. Among patients with intermediate risk features, this may translate to improved disease-free survival.
    MeSH term(s) Humans ; Positron Emission Tomography Computed Tomography/methods ; Carcinoma, Squamous Cell/diagnostic imaging ; Carcinoma, Squamous Cell/surgery ; Retrospective Studies ; Mouth Neoplasms/diagnostic imaging ; Mouth Neoplasms/surgery ; Squamous Cell Carcinoma of Head and Neck ; Fluorodeoxyglucose F18 ; Head and Neck Neoplasms ; Positron-Emission Tomography/methods
    Chemical Substances Fluorodeoxyglucose F18 (0Z5B2CJX4D)
    Language English
    Publishing date 2023-04-24
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 1120465-5
    ISSN 1879-0593 ; 0964-1955 ; 1368-8375
    ISSN (online) 1879-0593
    ISSN 0964-1955 ; 1368-8375
    DOI 10.1016/j.oraloncology.2023.106400
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.

    Li, Xingzhe / Kitpanit, Sarin / Lee, Anna / Mah, Dennis / Sine, Kevin / Sherman, Eric J / Dunn, Lara A / Michel, Loren S / Fetten, James / Zakeri, Kaveh / Yu, Yao / Chen, Linda / Kang, Jung Julie / Gelblum, Daphna Y / McBride, Sean M / Tsai, Chiaojung J / Riaz, Nadeem / Lee, Nancy Y

    JAMA network open

    2021  Volume 4, Issue 6, Page(s) e2113205

    Abstract: Importance: Patients with nonmetastatic nasopharyngeal carcinoma (NPC) are primarily treated by radiotherapy with curative intent with or without chemotherapy and often experience substantial treatment-related toxic effects even with modern radiation ... ...

    Abstract Importance: Patients with nonmetastatic nasopharyngeal carcinoma (NPC) are primarily treated by radiotherapy with curative intent with or without chemotherapy and often experience substantial treatment-related toxic effects even with modern radiation techniques, such as intensity-modulated radiation therapy (IMRT). Intensity-modulated proton therapy (IMPT) may improve the toxicity profile; however, there is a paucity of data given the limited availability of IMPT in regions with endemic NPC.
    Objective: To compare toxic effects and oncologic outcomes among patients with newly diagnosed nonmetastatic NPC when treated with IMPT vs IMRT with or without chemotherapy.
    Design, setting, and participants: This retrospective cohort study included 77 patients with newly diagnosed nonmetastatic NPC who received curative-intent radiotherapy with IMPT or IMRT at a tertiary academic cancer center from January 1, 2016, to December 31, 2019. Forty-eight patients with Epstein-Barr virus (EBV)-positive tumors were included in a 1:1 propensity score-matched analysis for survival outcomes. The end of the follow-up period was March 31, 2021.
    Exposures: IMPT vs IMRT with or without chemotherapy.
    Main outcomes and measures: The main outcomes were the incidence of acute and chronic treatment-related adverse events (AEs) and oncologic outcomes, including locoregional failure-free survival (LRFS), progression-free survival (PFS), and overall survival (OS).
    Results: We identified 77 patients (25 [32.5%] women; 52 [67.5%] men; median [interquartile range] age, 48.7 [42.2-60.3] years), among whom 28 (36.4%) were treated with IMPT and 49 (63.6%) were treated with IMRT. Median (interquartile range) follow-up was 30.3 (17.9-41.5) months. On multivariable logistic regression analyses, IMPT was associated with lower likelihood of developing grade 2 or higher acute AEs compared with IMRT (odds ratio [OR], 0.15; 95% CI, 0.03-0.60; P = .01). Only 1 case (3.8%) of a chronic grade 3 or higher AE occurred in the IMPT group compared with 8 cases (16.3%) in the IMRT group (OR, 0.21; 95% CI, 0.01-1.21; P = .15). Propensity score matching generated a balanced cohort of 48 patients (24 IMPT vs 24 IMRT) and found similar PFS in the IMPT and IMRT groups (2-year PFS, 95.7% [95% CI, 87.7%-100%] vs 76.7% [95% CI, 60.7%-97.0%]; hazard ratio [HR], 0.31; 95% CI, 0.07-1.47; P = .14). No locoregional recurrence or death was observed in the IMPT group from the matched cohort. Two-year LRFS was 100% (95% CI, 100%-100%) in the IMPT group and 86.2% (95% CI, 72.8%-100%) in the IMRT group (P = .08). Three-year OS was 100% (95% CI, 100%-100%) in the IMPT group and 94.1% (95% CI, 83.6%-100%) in the IMRT group (P = .42). Smoking history was the only clinical factor significantly associated with both poor LRFS (HR, 63.37; 95% CI, 3.25-1236.13; P = .006) and poor PFS (HR, 6.33; 95% CI, 1.16-34.57; P = .03) on multivariable analyses.
    Conclusions and relevance: In this study, curative-intent radiotherapy with IMPT for nonmetastatic NPC was associated with significantly reduced acute toxicity burden in comparison with IMRT, with rare late complications and excellent oncologic outcomes, including 100% locoregional control at 2 years. Prospective trials are warranted to direct the optimal patient selection for IMPT as the primary radiotherapy modality for nonmetastatic NPC.
    MeSH term(s) Adult ; Female ; Humans ; Male ; Middle Aged ; Nasopharyngeal Carcinoma/mortality ; Nasopharyngeal Carcinoma/therapy ; Propensity Score ; Proportional Hazards Models ; Prospective Studies ; Proton Therapy/adverse effects ; Proton Therapy/methods ; Radiotherapy, Intensity-Modulated/adverse effects ; Radiotherapy, Intensity-Modulated/methods ; Retrospective Studies ; Survival Rate ; Treatment Outcome ; United States
    Language English
    Publishing date 2021-06-01
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Research Support, N.I.H., Extramural
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2021.13205
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top